Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aura Biosciences, Inc. (AURA)

Aura Biosciences Q3 net loss widens to $32.1 million on restructuring costs

Negative Impact 3 of 5 earnings

Aura Biosciences reported third quarter 2026 results, with a net loss of $32.1 million, up from $26.1 million a year earlier. The company said a $4.5 million restructuring charge, tied to its reorganization around its ocular oncology portfolio, contributed to higher general and administrative expenses, and it reiterated that its cash is expected to last into the first half of 2029.

Key points

  • Net loss of $32.1 million for the quarter ended September 30, 2026, versus $26.1 million a year earlier; loss per share was $0.29, versus $0.40.
  • General and administrative expenses rose to $10.3 million from $5.7 million, driven mainly by restructuring charges of approximately $4.5 million.
  • Research and development expenses rose to $24.7 million from $22.2 million, tied to the Phase 3 CoMpass trial.
  • Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026.

The filing

CompanyAura Biosciences, Inc. (AURA)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:05 AM ET
Accession number0001193125-26-452620

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.